Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2023 4
2024 9
2025 31
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Linge J, Birkenfeld AL, Neeland IJ. Linge J, et al. Circulation. 2024 Oct 15;150(16):1288-1298. doi: 10.1161/CIRCULATIONAHA.124.067676. Epub 2024 Oct 14. Circulation. 2024. PMID: 39401279 Review.
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. ...This primer aims to address wh …
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonist …
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
Neeland IJ, Linge J, Birkenfeld AL. Neeland IJ, et al. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27. Diabetes Obes Metab. 2024. PMID: 38937282 Free article. Review.
Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor agonists is coming clo …
Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon …
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review.
Pantazopoulos D, Gouveri E, Papazoglou D, Papanas N. Pantazopoulos D, et al. Diabetes Res Clin Pract. 2025 Nov;229:112924. doi: 10.1016/j.diabres.2025.112924. Epub 2025 Sep 27. Diabetes Res Clin Pract. 2025. PMID: 41022269 Review.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual agonists targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors (GLP-1/GIP RAs) are established therapies fo …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual agonists targeting bo …
Muscle loss and GLP-1R agonists use.
Rossi G, Bucciarelli L, Mananguite CL, Giovarelli M, Fiorina P. Rossi G, et al. Acta Diabetol. 2026 Feb;63(2):333-342. doi: 10.1007/s00592-025-02611-2. Epub 2025 Nov 7. Acta Diabetol. 2026. PMID: 41201615 Free PMC article. Review.
The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have t …
The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases …
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, Green DJ. Locatelli JC, et al. Diabetes Care. 2024 Oct 1;47(10):1718-1730. doi: 10.2337/dci23-0100. Diabetes Care. 2024. PMID: 38687506 Review.
This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like pepti …
This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretin …
Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia.
Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Memel Z, et al. Curr Nutr Rep. 2025 Apr 28;14(1):63. doi: 10.1007/s13668-025-00649-w. Curr Nutr Rep. 2025. PMID: 40289060 Review.
PURPOSE OF REVIEW: Glucagon-like peptide- 1 receptor agonists (GLP- 1 RA) are a rapidly expanding class of medications used to treat many chronic diseases. ...This rapid and significant decline in muscle mass while taking …
PURPOSE OF REVIEW: Glucagon-like peptide- 1 receptor agonists (GLP- 1 RA) are a rapidly exp …
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Stefanakis K, Kokkorakis M, Mantzoros CS. Stefanakis K, et al. Metabolism. 2024 Dec;161:156057. doi: 10.1016/j.metabol.2024.156057. Epub 2024 Oct 30. Metabolism. 2024. PMID: 39481534 Review.
The myostatin-activin-follistatin-inhibin system, originally implicated in reproductive function and subsequently muscle regulation, appears to be crucial for muscle and bone maintenance during weight loss. ...Novel compounds in the pipeline, such as Bimagrum …
The myostatin-activin-follistatin-inhibin system, originally implicated in reproductive function and subsequently muscle regulation, …
Sarcopenic obesity and weight loss-induced muscle mass loss.
Caturano A, Amaro A, Berra CC, Conte C. Caturano A, et al. Curr Opin Clin Nutr Metab Care. 2025 Jul 1;28(4):339-350. doi: 10.1097/MCO.0000000000001131. Epub 2025 Apr 29. Curr Opin Clin Nutr Metab Care. 2025. PMID: 40296814 Free PMC article. Review.
PURPOSE OF REVIEW: Sarcopenic obesity is a clinical condition characterized by the coexistence of excess adiposity and impaired muscle function, associated with heightened cardiometabolic risk and frailty. The emergence of new incretin-based obesity management medications …
PURPOSE OF REVIEW: Sarcopenic obesity is a clinical condition characterized by the coexistence of excess adiposity and impaired muscle …
Glucagon-like peptide-1 receptor agonists and muscle mass effects.
Ceasovschih A, Asaftei A, Lupo MG, Kotlyarov S, Bartušková H, Balta A, Sorodoc V, Sorodoc L, Banach M. Ceasovschih A, et al. Pharmacol Res. 2025 Oct;220:107927. doi: 10.1016/j.phrs.2025.107927. Epub 2025 Aug 24. Pharmacol Res. 2025. PMID: 40858197 Free article. Review.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. ...This review critically exami …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of ob …
GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.
Scheen AJ. Scheen AJ. Diabetes Metab. 2025 Sep;51(5):101681. doi: 10.1016/j.diabet.2025.101681. Epub 2025 Jun 24. Diabetes Metab. 2025. PMID: 40571191 Free article. Review.
BACKGROUND: - Glucagon-like peptide-1 (GLP-1)-based therapies induce a clinically relevant weight loss, which is associated with overall better prognosis in people with type 2 diabetes and/or clinical obesity. ...Currently, availab …
BACKGROUND: - Glucagon-like peptide-1 (GLP-1)-based therapies induce a clinically relevant weight …
62 results